Compass Therapeutics Inc.
NASDAQ:CMPX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
T
|
Tofflon Science and Technology Group Co Ltd
SZSE:300171
|
CN |
|
E
|
Eagle Nice (International) Holdings Ltd
HKEX:2368
|
HK |
|
Immo Moury Sicaf Immobiliere Publique de Droit Belge SCA
LSE:0NUR
|
BE |
|
South Indian Bank Ltd
NSE:SOUTHBANK
|
IN |
Compass Therapeutics Inc.
Interest Expense
Compass Therapeutics Inc.
Interest Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
Compass Therapeutics Inc.
NASDAQ:CMPX
|
Interest Expense
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Interest Expense
$2.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
3%
|
CAGR 10-Years
15%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Interest Expense
$1B
|
CAGR 3-Years
3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Interest Expense
$2.8B
|
CAGR 3-Years
25%
|
CAGR 5-Years
17%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Interest Expense
$13.3m
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Interest Expense
$43.8m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
12%
|
|
Compass Therapeutics Inc.
Glance View
Compass Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of proprietary antibody therapeutics. The company is headquartered in Boston, Massachusetts and currently employs 24 full-time employees. The company went IPO on 2020-11-13. Its pipeline of product candidates includes both angiogenesis-targeted agents and immune-oncology focused agents. These product candidates are designed for anti-tumor response to cancer. Its lead product candidate, CTX-471, is a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells. Its second product candidate, CTX-8371, is a bispecific antibody that simultaneously targets both PD-1 and PD-L1, the targets of checkpoint inhibitor antibodies. In addition to CTX-471 and CTX-8371, It is also developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. Its product candidate, CTX-009, is an anti-DLL4 x VEGF-A bispecific antibody, which has added to its pipeline through Trigr Therapeutics, Inc. (TRIGR).
